Singapore: The Little Red Dot That Did | PharmaBoardroom

Singapore: The Little Red Dot That Did

face

singapore13illus640

I believe that the industry shall change its mindset and not focus all of its efforts on the right molecule but rather on understanding that first the right processes and business models need to be adopted too. Early adopters of SPAH Bea-cons technology can improve on their overall return rate & corporate performance. Expediting the launch of their molecules will in turn increase the possibility of finding a block-buster and once found their previous launch losses will be compensated. With SPAH the industry players can increase their chance of success mitigate their failures break out and lead the competition.

TAGS: ,,

Latest Report